Janus Henderson Horizon Biotechnology Fund H2 USDRegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 57.5 | -4.8 | 9.1 | 15.7 | 4.4 | |
+/-Cat | 31.5 | 4.2 | 16.9 | 17.0 | 8.2 | |
+/-B’mrk | 24.5 | -5.1 | 6.6 | 8.3 | -2.0 | |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 17/05/2024 | USD 24.38 | |
Day Change | 0.17% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU1897414485 | |
Fund Size (Mil) 30/04/2024 | USD 257.42 | |
Share Class Size (Mil) 17/05/2024 | USD 30.22 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 14/02/2024 | 1.26% |
Investment Objective: Janus Henderson Horizon Biotechnology Fund H2 USD |
The Sub-Fund aims to provide capital growth over the long term. The Fund invests at least 80% of its net assets in equities or equity-related instruments of biotechnology and biotechnology-related companies worldwide. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Daniel Lyons 10/12/2018 | ||
Agustin Mohedas 31/01/2023 | ||
Click here to see others | ||
Inception Date 10/12/2018 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Janus Henderson Horizon Biotechnology Fund H2 USD | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Vertex Pharmaceuticals Inc | Healthcare | 7.91 |
Amgen Inc | Healthcare | 7.83 |
Avadel Pharmaceuticals PLC ADR | Healthcare | 3.65 |
argenx SE ADR | Healthcare | 3.45 |
Sarepta Therapeutics Inc | Healthcare | 3.26 |
Increase Decrease New since last portfolio | ||
Janus Henderson Horizon Biotechnology Fund H2 USD |